What Is Epithalon?

Visao Geral da Pesquisa

Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide geroprotector developed by Prof. Vladimir Khavinson no(a) St. Petersburg Institute of Bioregulacao and Gerontology como o(a) ativo(a) component of Epithalamin (bovine pineal gland extract). Its discovery originated from 1970s Soviet military research para proteger soldiers from radiation and acelerou aging.[4]

Epithalon's mechanism is fundamentally diferente from classical receptor-ligand pharmacology. Rather do que binding a cell surface receptor, it enters the nucleus and interacts directly with DNA (targeting CAG repeats and ATTTC promoter sequences) and histone proteins (H1.3, H1.6) — functioning como um(a) epigenetic switch que converts heterochromatin to euchromatin, making silenced genes accessible for transcricao.[1][3]

Research spans 10+ indication categories across gerontology, oncology, ophthalmology, endocrinology, and neuroscience — with over 50 years of study (1970s–2025). The "Epithalon Paradox" — activating telomerase enquanto simultaneamente inhibiting cancer — challenges conventional oncological assumptions and remains a principal focus of current research.[7]